Smith Asset Management Group LP cut its position in OraSure Technologies, Inc. (NASDAQ:OSUR) by 26.2% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 322,987 shares of the medical instruments supplier’s stock after selling 114,877 shares during the period. Smith Asset Management Group LP’s holdings in OraSure Technologies were worth $5,575,000 at the end of the most recent quarter.
Other institutional investors have also recently bought and sold shares of the company. State Street Corp boosted its position in OraSure Technologies by 6.3% in the fourth quarter. State Street Corp now owns 1,346,519 shares of the medical instruments supplier’s stock worth $11,823,000 after buying an additional 79,922 shares during the last quarter. Norges Bank purchased a new position in OraSure Technologies during the fourth quarter worth about $9,786,000. Louisiana State Employees Retirement System purchased a new position in OraSure Technologies during the first quarter worth about $287,000. Nationwide Fund Advisors boosted its position in OraSure Technologies by 209.1% in the first quarter. Nationwide Fund Advisors now owns 144,922 shares of the medical instruments supplier’s stock worth $1,874,000 after buying an additional 98,034 shares during the last quarter. Finally, Fisher Asset Management LLC boosted its position in OraSure Technologies by 48.6% in the first quarter. Fisher Asset Management LLC now owns 503,594 shares of the medical instruments supplier’s stock worth $6,511,000 after buying an additional 164,630 shares during the last quarter. Hedge funds and other institutional investors own 90.12% of the company’s stock.
Shares of OraSure Technologies, Inc. (NASDAQ OSUR) opened at 20.73 on Friday. The stock has a market capitalization of $1.21 billion, a PE ratio of 38.32 and a beta of 1.57. OraSure Technologies, Inc. has a one year low of $6.84 and a one year high of $21.59. The company’s 50-day moving average price is $18.48 and its 200 day moving average price is $14.08.
OraSure Technologies (NASDAQ:OSUR) last released its quarterly earnings results on Wednesday, August 2nd. The medical instruments supplier reported $0.09 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.07 by $0.02. The company had revenue of $40.18 million during the quarter, compared to analyst estimates of $36.54 million. OraSure Technologies had a return on equity of 15.64% and a net margin of 22.29%. The firm’s revenue was up 28.1% on a year-over-year basis. During the same quarter last year, the business posted $0.07 earnings per share. Analysts anticipate that OraSure Technologies, Inc. will post $0.48 EPS for the current year.
OSUR has been the subject of a number of research reports. Jefferies Group LLC upped their price objective on OraSure Technologies from $12.00 to $16.00 and gave the stock a “buy” rating in a report on Thursday, May 4th. Zacks Investment Research upgraded OraSure Technologies from a “hold” rating to a “buy” rating and set a $18.00 price objective for the company in a report on Saturday, May 6th. Canaccord Genuity upped their price objective on OraSure Technologies from $15.00 to $18.00 and gave the stock a “buy” rating in a report on Wednesday, June 28th. Stephens reiterated an “overweight” rating and issued a $19.00 price objective (up from $14.00) on shares of OraSure Technologies in a report on Tuesday, July 11th. Finally, BidaskClub cut OraSure Technologies from a “strong-buy” rating to a “buy” rating in a report on Monday, July 24th. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. OraSure Technologies currently has an average rating of “Buy” and a consensus target price of $15.46.
In related news, SVP Jack E. Jerrett sold 73,463 shares of OraSure Technologies stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $20.77, for a total value of $1,525,826.51. Following the completion of the transaction, the senior vice president now owns 81,593 shares in the company, valued at $1,694,686.61. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Ronny B. Lancaster sold 89,684 shares of OraSure Technologies stock in a transaction dated Tuesday, May 30th. The stock was sold at an average price of $14.79, for a total value of $1,326,426.36. Following the completion of the transaction, the director now owns 6,295 shares of the company’s stock, valued at approximately $93,103.05. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,036,670 shares of company stock valued at $19,807,152. 7.80% of the stock is currently owned by company insiders.
About OraSure Technologies
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Want to see what other hedge funds are holding OSUR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OraSure Technologies, Inc. (NASDAQ:OSUR).
Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.